Revised SPC: Ibrance (palbociclib) capsules

Source:
electronic Medicines Compendium - eMC
Publisher:
electronic Medicines compendium
Publication date:
26 November 2019

Abstract

SPC now details interstitial lung disease/pneumonitis (ILD/P) as a potential adverse effect of treatment. Patients should be monitored, and treatment withheld should symptoms develop, and palbociclib should be permanently discontinued in the event of severe ILD/P.